Achilles Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	131.54	173.34	266.32	177.85	97.59
Cash & Cash Equivalents	131.54	173.34	266.32	177.85	97.59
Cash Growth	-24.11%	-34.91%	49.74%	82.23%	-
Other Current Assets	14.09	23.24	18.43	9.95	5.47
Total Current Assets	145.63	196.58	284.75	187.8	103.06
Property, Plant & Equipment	13.54	20.48	28.79	28.11	2.11
Long-Term Investments	0.03	0.03	0.03	0	0
Other Long-Term Assets	2.25	3.27	3.53	3.01	0.03
Total Long-Term Assets	15.82	23.78	32.36	31.12	2.14
Total Assets	161.46	220.36	317.11	218.92	105.21
Accounts Payable	5.63	5.19	3.72	6.31	0.9
Current Debt	3.54	4.19	4.48	3.71	0.49
Other Current Liabilities	7.83	8.62	10.91	6.6	2.47
Total Current Liabilities	17	17.99	19.11	16.62	3.86
Long-Term Debt	1.08	4.39	7.78	12.27	0
Other Long-Term Liabilities	1.02	0.93	0.69	0.65	0
Total Long-Term Liabilities	2.09	5.32	8.47	12.92	0
Total Liabilities	19.09	23.31	27.58	29.55	3.86
Total Debt	4.62	8.58	12.26	15.98	0.49
Debt Growth	-46.19%	-30.04%	-23.30%	3181.93%	-
Retained Earnings	-259.95	-190.29	-119.11	-58.01	-24.81
Comprehensive Income	-13.07	-21.7	6.64	12.32	8.11
Shareholders' Equity	142.37	197.04	289.53	189.37	101.35
Net Cash / Debt	126.92	164.76	254.06	161.87	97.11
Net Cash / Debt Growth	-22.97%	-35.15%	56.96%	66.69%	-
Net Cash Per Share	3.18	4.21	8.87	151.81	151.22
Working Capital	128.64	178.59	265.64	171.17	99.2
Book Value Per Share	3.56	5.03	10.10	177.61	157.82

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).